404 related articles for article (PubMed ID: 25273320)
1. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.
Kandathil A; Wong KK; Wale DJ; Zatelli MC; Maffione AM; Gross MD; Rubello D
Endocrine; 2015 May; 49(1):6-26. PubMed ID: 25273320
[TBL] [Abstract][Full Text] [Related]
2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
3. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of unenhanced computed tomography and
Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
[TBL] [Abstract][Full Text] [Related]
7. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
9. Radiologic evaluation of incidentally discovered adrenal masses.
Willatt JM; Francis IR
Am Fam Physician; 2010 Jun; 81(11):1361-6. PubMed ID: 20521756
[TBL] [Abstract][Full Text] [Related]
10. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
Boland GW; Blake MA; Holalkere NS; Hahn PF
AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
[TBL] [Abstract][Full Text] [Related]
11. Contemporary imaging of incidentally discovered adrenal masses.
Wale DJ; Wong KK; Viglianti BL; Rubello D; Gross MD
Biomed Pharmacother; 2017 Mar; 87():256-262. PubMed ID: 28063406
[TBL] [Abstract][Full Text] [Related]
12. Adrenal masses of varied etiology: anatomical and molecular imaging features on PET-CT.
Sharma P; Singh H; Dhull VS; Suman KC S; Kumar A; Bal C; Kumar R
Clin Nucl Med; 2014 Mar; 39(3):251-60. PubMed ID: 24217551
[TBL] [Abstract][Full Text] [Related]
13. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
14. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer.
Vikram R; Yeung HD; Macapinlac HA; Iyer RB
AJR Am J Roentgenol; 2008 Nov; 191(5):1545-51. PubMed ID: 18941099
[TBL] [Abstract][Full Text] [Related]
15. Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center.
Maciel J; Cavaco D; Fraga D; Donato S; Simões H; Sousa R; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):131-138. PubMed ID: 36477790
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?
Tessonnier L; Sebag F; Palazzo FF; Colavolpe C; De Micco C; Mancini J; Conte-Devolx B; Henry JF; Mundler O; Taïeb D
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2018-25. PubMed ID: 18566816
[TBL] [Abstract][Full Text] [Related]
18. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
19. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
20. Cystic adrenal masses: spectrum of multimodality imaging features and pathological correlation.
Wang MX; Mahmoud HS; Klimkowski S; Salem U; Korivi BR; Corwin M; Ahmed AM; Shaaban AM; Menias CO; Elsayes KM
Clin Radiol; 2022 Jul; 77(7):479-488. PubMed ID: 35428471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
